Hereby, we present a 20-year-old patient with HSP that developed during isotretinoin treatment for his acne.
A 20-year-old man presented at our outpatient clinic with palpable purpuric lesions developed after the fourth week of isotreinoin (30 mg/day) treatment for severe inflammatory acne. Examination revealed multiple palpable purpura on the legs, 1 mm to 15 mm in diameter (Fig. 1) . Furthermore, the patient had arthralgia in both ankles and knees. ( Fig. 2) . On histopathological examination, in support of the relationship between vasculitis and the drug, quite a few eosinophilic infiltration in addition to perivascular neutrophilic infiltration was observed (Fig. 2B ). According to these clinical and histopathological findings, the patient was diagnosed with having HSP. Isotretinoin treatment was discontinued; low-dose steroid therapy (fluocortolon 20 mg/day) was initiated and continued 3 weeks. All lesions disappeared by 2 weeks and the disease did not relapse during the 2 months' follow-up. According to EULAR/PRES/PRINTO (European League Against Rheumatism / Paediatric Rheumatology European Society / Paediatric Rheumatology International Trials Organisation), the criterion of palpable purpura or of petechia with lower limb predominance is mandatory criterion for the diagnosis of HSP. Furthermore, at least one of the following criteria must be present: diffuse abdominal pain, IgA deposition in any biopsy, arthritis/ arthralgia, and renal involvement 2 . The most common causes of HSP are infections of respiratory, gastrointestinal, and genitourinary tracts. Other well-known triggering factors of the disease are hepatic infections, inflammatory bowel disease, autoimmune rheumatic diseases, hematological and solid organ malignancies, vaccinations and adverse drug reactions to diverse drugs. Use of isotretinoin was the sole suspected cause of HSP in our case. Isotretinoin induced vasculitis is very rare in the literature. Dwyer et al. 3 reviewed 11 isolated vasculitis cases, which could have been associated with isotretinoin and were gathered by manufacturer of isotretinoin. In the manufacturer's judgment, 5 of the 11 patients the leucocytoclastic vasculitis was associated with the use of systemic isotretinoin. There were no other factors other than retinoid use that may have caused vasculitis in these patients except for 1 patient who had streptococcal infection.
Reynolds et al. 4 reported a case of disseminated vasculitis, which developed 6 weeks after completion of isotretinoin treatment. However, some authors argued that this cause was controversial considering a serum half-life of isotretinoin 5 . Epstein et al. 6 described 2 patients who developed severe vasculitis in whom one patient with Wegener's granulomatosis and the other patient with small-vessel angiitis, while receiving isotretinoin for severe cystic acne. Chochrad et al. 7 reported a case of 'polyarteritis-like vasculitis' associated with isotretinoin. It is interesting that despite these early reports of vasculitis associated with isotretinoin, in a PubMed search we could not detect any other reports after 1997. The reason may be associated with a rare occurrence of cases, alternatively further cases may have not been reported. In addition, it is not possible to make a definitive diagnosis. Instead, the diagnosis of drug induced vasculitis is based on a temporal relationship between exposure to the agent and the development of vasculitis and the exclusion of other factors.
In our case, we couldn't find any causal factor other than treatment with isotretinoin. Although rare, the clinicians should remember retinoid medications as a possible cause of vasculitis.
